Navigation Links
Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference

WORCESTER, Mass. and TORONTO, Sept. 7, 2011 /PRNewswire/ -- Generex Biotechnology Corporation ( (OTCBB: GNBT) announced today that Mark Fletcher, the Company's President & Chief Executive Officer, and Dr. Eric von Hofe, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. ( will make a Generex/Antigen presentation at  the Rodman & Renshaw 13th Annual Healthcare Conference.  The presentation will take place at 4:45 pm ET on September 12, 2011 in the Starlight North room at the Waldorf Astoria Hotel in New York City.


About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at or the Antigen Express website at

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
2. Generex Provides Corporate Update
3. Generex Provides Preliminary Results of Generex Oral-lyn™ Clinical Trials in Patients with Type 1 Diabetes and Patients with Impaired Glucose Tolerance
4. Generex Announces Appointment of CEO for Post-Spinout Antigen Express
5. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
6. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
7. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at
8. Generex Biotechnology Corporation CEO to Present Live, Online at on May 5th
9. Generex Launches New Corporate Website
10. Generex Unveils Strategic Development Plan
11. Generex Plans Rights Offering Upon Approval of Reverse Stock Split and Listing on a National Stock Exchange
Post Your Comments:
(Date:10/13/2015)... World Thrombosis Day Interactive Infographic ...   --> World Thrombosis Day Interactive ... promote vital global awareness of thrombosis, its causes, ... the formation of potentially deadly blood clots in ... thromboembolism (VTE) - or the artery (arterial thrombosis) [1] ...
(Date:10/12/2015)... the United States . By early next year, ... the United States . By early next year, ... The University of Texas MD Anderson Cancer Center, Elekta and ... Tesla) MRI-guided linear accelerator in the United States ... a non-clinical capacity. Royal Philips (NYSE: PHG ...
(Date:10/12/2015)... , Oct. 12, 2015 ... the setbacks and the needs of the medical membrane ... of membrane devices within the different medical membrane devices ... blood microfilters/apheresis systems and membrane diagnostic devices. - Gain ... in this market. --> Use this report ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN ... orbital fracture when a teammate accidentally elbowed him in the left eye during the ... injury is just one of a series of setbacks, including a knee injury that ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... as the newest professional to introduce the latest development, ThermiVa® temperature controlled radiofrequency ... a leading professional in Obstetrics and Gynecology and a pioneer in the field ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Affinity have developed valuable new strategies for enrolling and serving insurance consumers who ... to obtain health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... the Florida Apartment Association (FAA) has partnered with the Florida Department of Health ... demand. , The FAA Smoke-Free Multifamily Housing Program launched last week at ...
(Date:10/13/2015)... ... ... Just under three months ago, eMarketing Concepts forever changed the ... offering all of their services for just a buck in the first month. The ... calls from interested buyers. As a genuine one-stop-shop for internet marketing, EMC has cornered ...
Breaking Medicine News(10 mins):